Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.

Jan Westerink,Kasper Sommer Matthiessen,Solomon Nuhoho,Udi Fainberg,Michael Lyng Wolden,Helena Bleken Østergaard,Frank Visseren,Naveed Sattar

Diabetes care（2022）

引用 9|浏览18

暂无评分

摘要

Adding semaglutide to SoC was associated with a gain in life-years free of CVD events that was dependent on baseline CVD risk and age at treatment initiation. This study helps contextualize the results of semaglutide clinical trials.

查看译文

关键词

semaglutide,high cardiovascular risk,cardiovascular risk,recurrent major cardiovascular events,diabetes,life-years

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要